Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | IGF1R | P08069 | 2/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.60 |
| ▸ | TNK2 | Q07912 | 12/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.49 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.49 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.49 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939904 | 0.85 | RAF1 (0.69) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL6942151 | 0.84 | RAF1 (0.68) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL6940312 | 0.84 | RAF1 (0.77) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL6936144 | 0.84 | RAF1 (0.74) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL593776 | 0.84 | RAF1 (0.69) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL8179182 | 0.83 | RAF1 (0.81) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL8076281 | 0.83 | RAF1 (0.81) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL12165267 | 0.83 | RAF1 (0.71) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL6936666 | 0.83 | SRC (0.75) | RAF1SRCIGF1RPDPK1ABL1 | |
| SCHEMBL595008 | 0.83 | RAF1 (0.68) | RAF1SRCIGF1RPDPK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | RAF1 537/4885SRC 151/4885IGF1R 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.